Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-323 DDI with midazolam, caffeine, and rosuvastatin
NCT06917508Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EDP-323 in respiratory syncytial virus infection (RSV), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration up to 17 Days and Area Under the Curve up to 17 Days. Started Mar 2025; status: completed.
02
Drugs
EDP-323
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06917508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917508.